2023
Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial
Grilo C, Lydecker J, Jastreboff A, Pittman B, McKee S. Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial. Obesity 2023, 31: 2762-2773. PMID: 37751990, PMCID: PMC10600891, DOI: 10.1002/oby.23898.Peer-Reviewed Original ResearchConceptsNaltrexone/bupropionBinge-eating disorderObesity statusLogistic regressionWeight lossPlacebo-controlled trialWeight loss outcomesPrevalent psychiatric disordersEvidence-based treatmentsPost-treatment assessmentBinge-eating frequencyGreater percentage weight lossMedication outcomesRemission ratePharmacological optionsPlaceboBupropionPsychiatric disordersPercentage weight lossMixed modelsDisordersObesityPatientsSignificant reductionWeight reduction
2016
Binge abstinence is associated with reduced energy intake after treatment in patients with binge eating disorder and obesity
Masheb RM, Dorflinger LM, Rolls BJ, Mitchell DC, Grilo CM. Binge abstinence is associated with reduced energy intake after treatment in patients with binge eating disorder and obesity. Obesity 2016, 24: 2491-2496. PMID: 27797154, PMCID: PMC5172456, DOI: 10.1002/oby.21664.Peer-Reviewed Original ResearchConceptsCognitive behavioral therapyPsychological functioningBinge abstinencePsychological outcomesCombination of CBTBehavioral therapyBingeRecall interviewsFunctioningAbstinence ratesDietary recall interviewsReduced energy intakeAbstinenceSignificant reductionWeight statusPsychiatric morbidityGreater improvementAdult patientsDietary counselingFruit intakeSugar intakeEnergy intakeDisordersAbstinentComplete cessation